Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04036292 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
A Phase 3 study of Dry Eye Disease (DED), sponsored by Oyster Point Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 758
- Enrollment target
- 20
- Study locations
NCT04036292 is a Phase 3 study of Dry Eye Disease (DED) that has completed, run by Oyster Point Pharma. The registered enrollment target is 758 participants, above the 239-participant average among 3 other Dry Eye Disease (DED) trials with a reported enrollment target (217% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT04036292, a Phase 3 study of Dry Eye Disease (DED), has completed, sponsored by Oyster Point Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 758 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
Conditions Studied
Interventions
- DRUG Placebo (vehicle) nasal spray
- DRUG OC-01 (varenicline) nasal spray
Study Locations (20)
Texas
- Austin - Austin
- Houston - Houston
- San Antonio - San Antonio
- San Antonio - San Antonio
North Carolina
- Raleigh - Raleigh
- Shelby - Shelby
Arizona
- Phoenix - Phoenix
California
- New Port Beach - Newport Beach
Colorado
- Fort Collins - Fort Collins
Connecticut
- Waterbury - Waterbury
Florida
- Delray Beach - Delray Beach
Indiana
- Indianapolis - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 758 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2021-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04036292
The ClinicalTrials.gov registry entry for NCT04036292 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 758 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 239-participant average among 3 other Dry Eye Disease (DED) trials with a reported enrollment target (217% higher). The listed sponsor is Oyster Point Pharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease (DED) appearing as the primary indexed condition, and to 2 interventions - of which Placebo (vehicle) nasal spray is the first listed.
NCT04036292 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Texas, North Carolina, Arizona.
Frequently Asked Questions
What is clinical trial NCT04036292 about?
NCT04036292 is a clinical study titled "Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease". The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.
What is the current status of trial NCT04036292?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 758 participants. The study started on 2019-07-23. Estimated completion is 2021-02-05.
What conditions does trial NCT04036292 study?
This clinical trial studies the following conditions: Dry Eye Disease (DED).
What interventions are being tested in trial NCT04036292?
The interventions under investigation include: Placebo (vehicle) nasal spray (DRUG), OC-01 (varenicline) nasal spray (DRUG).
Who is sponsoring clinical trial NCT04036292?
This trial is sponsored by Oyster Point Pharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04036292 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease (DED)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)
COMPLETED · Phase 3
-
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
COMPLETED · Phase 3
-
Evaluating Crosslinked Hyaluronate Canalicular Gel for the Treatment of DED in Patients Undergoing Cataract Surgery
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.